A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Bevacizumab for Recurrent Glioblastoma Multiforme: A Meta-Analysis

(2017) Eric T. Wong et al.   Journal of the National Comprehensive Cancer Network

Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time

(2015) Mi Zhou et al.   INTERNATIONAL JOURNAL OF CANCER

LB-05PHASE III TRIAL EXPLORING THE COMBINATION OF BEVACIZUMAB AND LOMUSTINE IN PATIENTS WITH FIRST RECURRENCE OF A GLIOBLASTOMA: THE EORTC 26101 TRIAL

(2015) W. Wick et al.   NEURO-ONCOLOGY

High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2014) R. Stupp et al.   ANNALS OF ONCOLOGY

First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

(2014) Jordi Rodon et al.   CLINICAL CANCER RESEARCH

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

(2014) Jordi Rodón et al.   INVESTIGATIONAL NEW DRUGS

Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

(2013) Ivelina Gueorguieva et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme

(2013) R. M. Bambury et al.   JOURNAL OF NEURO-ONCOLOGY

Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies

(2012) Sameer Agnihotri et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

(2012) D. S. Chen et al.   CLINICAL CANCER RESEARCH

Abstract C201: The combination of the small molecule TGF R1 inhibitor LY2157299 monohydrate with CCNU substantially blocks SMAD phosphorylation and significantly suppresses human glioblastoma xenograft growth.

(2012) S. Parsons et al.   MOLECULAR CANCER THERAPEUTICS

IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee

(2011) M. Preusser et al.   CLINICAL NEUROPATHOLOGY

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab

(2011) J. S. Wefel et al.   NEURO-ONCOLOGY

TGF-β Receptor Inhibitors Target the CD44high/Id1high Glioma-Initiating Cell Population in Human Glioblastoma

(2010) Judit Anido et al.   CANCER CELL

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Ongoing Clinical Trials

(2010) J. L. Clarke et al.   NEURO-ONCOLOGY

TGF-β Increases Glioma-Initiating Cell Self-Renewal through the Induction of LIF in Human Glioblastoma

(2009) Silvia Peñuelas et al.   CANCER CELL

Modulation of TGF-β activity by latent TGF-β-binding protein 1 in human malignant glioma cells

(2009) Isabel Tritschler et al.   INTERNATIONAL JOURNAL OF CANCER

Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology

(2009) Hideaki Tahara et al.   Journal of Translational Medicine

Randomization by minimization for unbalanced treatment allocation

(2009) Baoguang Han et al.   STATISTICS IN MEDICINE

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology

(2008) Alba A. Brandes et al.   NEURO-ONCOLOGY

Lactate promotes glioma migration by TGF-β2–dependent regulation of matrix metalloproteinase-2

(2008) Fusun Baumann et al.   NEURO-ONCOLOGY